In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on RedHill Biopharma (NASDAQ: RDHL), with a price target of $36. The company’s shares closed yesterday at $5.49.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 4.3% and a 35.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.
RedHill Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $36.
See today’s analyst top recommended stocks >>
Based on RedHill Biopharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $10.71 million. In comparison, last year the company had a GAAP net loss of $8.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RedHill Biopharma Ltd. is a biopharmaceutical company, which is focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. The company’s gastrointestinal products include Donnatal and EnteraGam.
